Menopause Market Report 2026

Menopause Market Overview

• Menopause market size has reached to $18.78 billion in 2025 • Expected to grow to $26.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Changing Lifestyle And Its Impact On The Menopause Market • Market Trend: Innovative Dual NK1/NK3 Therapy Offers Hormone-Free Relief For Hot Flashes And Night Sweats • North America was the largest region in 2025.

What Is Covered Under Menopause Market?

Menopause is a natural biological process that marks the end of a woman's menstrual cycles and reproductive years, diagnosed after a woman has gone 12 consecutive months without a menstrual period. It is often associated with various physical and hormonal changes signaling the end of the reproductive years when the ovaries stop releasing eggs and the hormones progesterone and estrogen become less abundant. The main treatments for menopause are dietary supplements and over the counter (OTC) pharma products. A dietary supplement is a substance that, unlike regular food, is meant to complement the diet. The various routes of administration involved are topical, oral, and injectables channeled through hospitals, retail, and online pharmacies and used by hospitals, diagnostic centers, specialty clinics, and other end users.

What Is The Menopause Market Growth Forecast?

The menopause market size is expected to see strong growth in the next few years. It will grow to $26.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for safer long-term therapies, growth in menopause-focused digital health platforms, increasing focus on preventive women’s health, expansion of online pharmacy access, greater acceptance of alternative and lifestyle-based treatments. Major trends in the forecast period include growing adoption of non-hormonal menopause treatments, rising awareness and proactive menopause management, increasing preference for dietary supplements and natural remedies, expansion of personalized menopause care programs, higher demand for symptom-specific treatment solutions.

What Is The Driver Of The Menopause Market?

The increase in changing lifestyle is expected to propel the growth of the menopause market going forward. A changing lifestyle refers to shifts in how individuals live and make choices that impact their health and well-being. During this normal biological phase, lifestyle adjustments can help control menopausal symptoms and enhance general health. Menopause may be utilized to alter lifestyle choices in several ways, including eating a good diet, exercising frequently, getting enough sleep, abstaining from smoking and drinking excessive amounts of alcohol, and engaging in soothing hobbies. For instance, in November 2023, according to press released by Global Wellness Institution, a US-based organization, in 2022, the wellness economy represented 5.6% of global economic output and is projected to grow to $8.5 trillion by 2027, with an average annual growth rate of 8.6%. Therefore, the increasing in changing lifestyle is driving the growth of the menopause industry.

Key Players In The Global Menopause Market

Major companies operating in the menopause market are Pfizer Inc., Johnson & Johnson Inc., The Procter & Gamble Company, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A, Abbott Laboratories Ltd., GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Rainbow Light Nutritional Systems LLC, Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex SpA, Pure Encapsulations LLC., Mylan N.V., Serenity Pharmaceuticals LLC

Global Menopause Market Trends and Insights

Major companies operating in the menopause market are focusing on developing innovative therapies, such as dual neurokinin 1/neurokinin 3 (NK1/NK3) receptor antagonists, to offer hormone-free alternatives for vasomotor symptoms (hot flashes and night sweats) and improve quality of life for menopausal women. Dual neurokinin 1/neurokinin 3 receptor antagonists refer to oral pharmaceuticals that simultaneously block both NK1 and NK3 receptors in the hypothalamus, thereby modulating the neuropeptide pathways responsible for thermoregulation and sweat responses and reducing the frequency and severity of hot flashes and associated sleep disturbances. For instance, in October 2025, Bayer AG, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Lynkuet (elinzanetant) 60 mg capsules, the world’s first dual-NK1/NK3 receptor antagonist approved for the treatment of moderate to severe hot flashes due to menopause. Lynkuet offers once-daily bedtime dosing, significant reductions in both frequency and severity of hot flashes as demonstrated in three Phase III trials (OASIS 1/2/3), and a non-hormonal mechanism of action that broadens treatment options for women contraindicated for hormone therapy.

What Are Latest Mergers And Acquisitions In The Menopause Market?

In December 2023, Theramex HQ UK Limited, a UK-based global specialty pharmaceutical company focused on women’s health, acquired the Femoston and Duphaston hormone replacement therapy portfolio in Europe from Viatris Inc. for an undisclosed amount. Through this acquisition, Theramex aims to strengthen its menopause treatment portfolio by expanding access to established hormone replacement therapies used to manage menopausal symptoms across multiple European markets. Viatris Inc. is a US-based pharmaceutical company that provides menopause therapies, previously held the European rights to Femoston and Duphaston.

What Defines the Menopause Market?

The menopause market includes revenues earned by entities by providing hormone replacement therapies, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Menopause Market Report 2026?

The menopause market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the menopause industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.